These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19862658)

  • 1. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
    Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC
    Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.
    Raatschen HJ; Simon GH; Fu Y; Sennino B; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Radiology; 2008 May; 247(2):391-9. PubMed ID: 18372448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).
    Cyran CC; Sennino B; Fu Y; Rogut V; Shames DM; Chaopathomkul B; Wendland MF; McDonald DM; Brasch RC; Raatschen HJ
    Eur J Radiol; 2012 May; 81(5):891-6. PubMed ID: 21889860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow versus permeability weighting in estimating the forward volumetric transfer constant (K
    Li CH; Chen FH; Schellingerhout D; Lin YS; Hong JH; Liu HL
    Magn Reson Imaging; 2017 Feb; 36():105-111. PubMed ID: 27989901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular permeability to macromolecules in human melanoma xenografts assessed by contrast-enhanced MRI--intertumor and intratumor heterogeneity.
    Bjørnaes I; Rofstad EK
    Magn Reson Imaging; 2001 Jun; 19(5):723-30. PubMed ID: 11672631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer.
    Raatschen HJ; Fischer S; Zsivcsec B; Schoenfeld CO; Hotz B; Buhr HJ; Hotz HG
    Acta Radiol; 2014 Mar; 55(2):131-9. PubMed ID: 23892234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.
    Raatschen HJ; Fu Y; Brasch RC; Pietsch H; Shames DM; Yeh BM
    Invest Radiol; 2009 May; 44(5):265-70. PubMed ID: 19346961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
    Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
    J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution.
    Demsar F; Roberts TP; Schwickert HC; Shames DM; van Dijke CF; Mann JS; Saeed M; Brasch RC
    Magn Reson Med; 1997 Feb; 37(2):236-42. PubMed ID: 9001148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
    Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
    Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
    Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
    Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
    Preda A; Wielopolski PA; Ten Hagen TL; van Vliet M; Veenland JF; Ambagtsheer G; van Tiel ST; Vogel MW; Eggermont AM; Krestin GP; van Dijke CF
    MAGMA; 2004 Dec; 17(3-6):296-302. PubMed ID: 15480945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
    Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
    Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.